Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer - PubMed
Clinical Trial
. 2015 Jan;26(1):141-148.
doi: 10.1093/annonc/mdu472. Epub 2014 Oct 14.
K Higuchi 2 , K Nishikawa 3 , M Gotoh 4 , N Fuse 5 , N Sugimoto 6 , T Nishina 7 , K Amagai 8 , K Chin 9 , Y Niwa 10 , A Tsuji 11 , H Imamura 12 , M Tsuda 13 , H Yasui 14 , H Fujii 15 , K Yamaguchi 16 , H Yasui 17 , S Hironaka 18 , K Shimada 19 , H Miwa 20 , C Hamada 21 , I Hyodo 22
Affiliations
- PMID: 25316259
- DOI: 10.1093/annonc/mdu472
Free article
Clinical Trial
Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer
Y Yamada et al. Ann Oncol. 2015 Jan.
Free article
Abstract
Background: We evaluated the efficacy and safety of S-1 plus oxaliplatin (SOX) as an alternative to cisplatin plus S-1 (CS) in first-line chemotherapy for advanced gastric cancer (AGC).
Patients and methods: In this randomized, open-label, multicenter phase III study, patients were randomly assigned to receive SOX (80-120 mg/day S-1 for 2 weeks with 100 mg/m(2) oxaliplatin on day 1, every 3 weeks) or CS (S-1 for 3 weeks with 60 mg/m(2) cisplatin on day 8, every 5 weeks). The primary end points were noninferiority in progression-free survival (PFS) and relative efficacy in overall survival (OS) for SOX using adjusted hazard ratios (HRs) with stratification factors; performance status and unresectable or recurrent (+adjuvant chemotherapy) disease.
Results: Overall, 685 patients were randomized from January 2010 to October 2011. In per-protocol population, SOX (n = 318) was noninferior to CS (n = 324) in PFS [median, 5.5 versus 5.4 months; HR 1.004, 95% confidence interval (CI) 0.840-1.199; predefined noninferiority margin 1.30]. The median OS for SOX and CS were 14.1 and 13.1 months, respectively (HR 0.958 with 95% CI 0.803-1.142). In the intention-to-treat population (SOX, n = 339; CS, n = 337), the HRs in PFS and OS were 0.979 (95% CI 0.821-1.167) and 0.934 (95% CI 0.786-1.108), respectively. The most common ≥grade 3 adverse events (SOX versus CS) were neutropenia (19.5% versus 41.8%), anemia (15.1% versus 32.5%), hyponatremia (4.4% versus 13.4%), febrile neutropenia (0.9% versus 6.9%), and sensory neuropathy (4.7% versus 0%).
Conclusion: SOX is as effective as CS for AGC with favorable safety profile, therefore SOX can replace CS.
Clinical trial number: JapicCTI-101021.
Keywords: S-1; advanced gastric cancer; cisplatin; oxaliplatin; phase III study.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Similar articles
-
Nishina T, Azuma M, Nishikawa K, Gotoh M, Bando H, Sugimoto N, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Mitome T, Kageyama H, Hyodo I. Nishina T, et al. Gastric Cancer. 2019 Jan;22(1):138-146. doi: 10.1007/s10120-018-0845-7. Epub 2018 Jun 9. Gastric Cancer. 2019. PMID: 29948386
-
Hamada C, Yamada Y, Azuma M, Nishikawa K, Gotoh M, Bando H, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hyodo I. Hamada C, et al. Int J Clin Oncol. 2016 Aug;21(4):668-675. doi: 10.1007/s10147-015-0938-9. Epub 2016 Jan 5. Int J Clin Oncol. 2016. PMID: 26733020 Review.
-
Lee KW, Chung IJ, Ryu MH, Park YI, Nam BH, Oh HS, Lee KH, Han HS, Seo BG, Jo JC, Lee HR, Kim JW, Park SR, Cho SH, Kang YK; SOPP study investigators. Lee KW, et al. Gastric Cancer. 2021 Jan;24(1):156-167. doi: 10.1007/s10120-020-01101-4. Epub 2020 Jun 28. Gastric Cancer. 2021. PMID: 32596783 Clinical Trial.
-
Xiao C, Qian J, Zheng Y, Song F, Wang Q, Jiang H, Mao C, Xu N. Xiao C, et al. Medicine (Baltimore). 2019 May;98(20):e15696. doi: 10.1097/MD.0000000000015696. Medicine (Baltimore). 2019. PMID: 31096513 Free PMC article. Clinical Trial.
-
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O, Elsayed Z, Elhalawani H. Abdel-Rahman O, et al. Cochrane Database Syst Rev. 2018 Apr 6;4(4):CD011746. doi: 10.1002/14651858.CD011746.pub2. Cochrane Database Syst Rev. 2018. PMID: 29624208 Free PMC article. Review.
Cited by
-
Mao C, He Y, Xu N, Yan H, Zhang N, Cheng G, Jiang H, Chen M, Chen Y, Wang X, Gu Y, Shen P, Zhang G, Yan J, Yang Z, Ding L, Han Z, Wang Z, Zhang J, Zheng W, Wang J, Qin S. Mao C, et al. Immun Inflamm Dis. 2024 Aug;12(8):e1348. doi: 10.1002/iid3.1348. Immun Inflamm Dis. 2024. PMID: 39105572 Free PMC article.
-
Zhang X, Xu S, Wang J, Lv Y, Wang N, Lai R, Sha Z, Zhao Q, Guo Z. Zhang X, et al. BMC Cancer. 2022 Nov 5;22(1):1136. doi: 10.1186/s12885-022-10199-x. BMC Cancer. 2022. PMID: 36335320 Free PMC article.
-
Kawase T, Imamura H, Kawabata R, Matsuyama J, Nishikawa K, Yanagihara K, Yamamoto K, Hoki N, Kawada J, Kawakami H, Sakai D, Kurokawa Y, Shimokawa T, Satoh T. Kawase T, et al. Int J Clin Oncol. 2024 Feb;29(2):134-141. doi: 10.1007/s10147-023-02437-4. Epub 2024 Jan 16. Int J Clin Oncol. 2024. PMID: 38227090 Clinical Trial.
-
Bu ZJ, Wan SR, Steinmann P, Yin ZT, Tan JP, Li WX, Tang ZY, Jiang S, Ye MM, Xu JY, Zheng YY, Wang XH, Liu JP, Liu ZL. Bu ZJ, et al. J Cancer. 2024 Jan 1;15(4):889-907. doi: 10.7150/jca.91301. eCollection 2024. J Cancer. 2024. PMID: 38230219 Free PMC article.
-
Kim HS, Ryu MH, Zang DY, Ryoo BY, Yang DH, Cho JW, Lim MS, Kim MJ, Han B, Choi DR, Kim JH, Jung JY, Song H, Park CK, Kang YK. Kim HS, et al. Gastric Cancer. 2016 Apr;19(2):579-585. doi: 10.1007/s10120-015-0503-2. Epub 2015 May 22. Gastric Cancer. 2016. PMID: 25997815 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous